Abstract
Meeting abstracts Intralesional therapies offer promise to modulate immune signatures within melanoma and other cancers, either as monotherapy or as a component of combination immune therapy. We have shown that the TLR2/6 agonists (MALP-2 and FSL-1) and IFNγ induce human melanoma cells to
Highlights
Intralesional therapies offer promise to modulate immune signatures within melanoma and other cancers, either as monotherapy or as a component of combination immune therapy
TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling
We have shown that the TLR2/6 agonists (MALP-2 and FSL-1) and IFNg induce human melanoma cells to synergistically produce T-cell attracting chemokine CXCL10
Summary
Intralesional therapies offer promise to modulate immune signatures within melanoma and other cancers, either as monotherapy or as a component of combination immune therapy. Mauldin et al Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P225 http://www.immunotherapyofcancer.org/content/2/S3/P225 TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
